The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic Leukemia
NCT07515430 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 138
Last updated 2026-04-07
Summary
This study is a prospective longitudinal investigation. Data on disease-related information, gut microbiota composition, cancer-related symptoms, dietary intake, and levels of pro-inflammatory cytokines, LPS were collected repeatedly at the following time points: before chemotherapy initiation, at the end of induction chemotherapy or Re-induction I, at 8 weeks after induction or re-induction therapy, at three months after induction or re-induction therapy, as well as weekly between chemotherapy initiation and the end of induction chemotherapy or Re-induction I. The aim is to explore the relationship between gut microbiota composition and cancer-related symptoms.
Conditions
Interventions
- OTHER
-
Questionnaires set
Planned to undergo a complete cycle of induction chemotherapy, with repeated collection of data including disease-related information, cancer-related symptoms, dietary records, and pro-inflammatory cytokine questionnaires. These data will be collected at the following time points: before the initiation of chemotherapy, upon completion of induction chemotherapy or Re-induction I, at 8 weeks post-induction or re-induction therapy, at three months post-induction or re-induction therapy, as well as weekly from the start of chemotherapy until the end of induction chemotherapy or Re-induction I.
- OTHER
-
fecal sample collecting
Planned to undergo a complete cycle of induction chemotherapy, with repeated collection of fecal sample. These data will be collected at the following time points: before the initiation of chemotherapy, upon completion of induction chemotherapy or Re-induction I, at 8 weeks post-induction or re-induction therapy, at three months post-induction or re-induction therapy, as well as weekly from the start of chemotherapy until the end of induction chemotherapy or Re-induction I.
Sponsors & Collaborators
-
Sun Yat-sen University
lead OTHER
Principal Investigators
-
Wei Xia, Phd · Sun Yat-sen University
Eligibility
- Min Age
- 5 Years
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-02-01
- Primary Completion
- 2026-12-01
- Completion
- 2026-12-01
Countries
- China
Study Locations
More Related Trials
-
Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors
NCT07450872 ·Status: RECRUITING
-
Exploring the Predictive Effect of Intestinal and Oral Microbiota on the Efficacy of Neoadjuvant Radiotherapy and Chemotherapy for Locally Advanced Rectal Cancer Based on Machine Learning
NCT07346729 ·Status: COMPLETED
-
Association Between the Composition of the Intestinal Microbiota and Tumor Response in Locally Advanced Rectal Cancer
NCT06181201 ·Status: TERMINATED
-
Role of Gut Microbiota in Neoadjuvant Radioimmunotherapy for MSS, Locally Advanced Rectal Cancer
NCT06898359 ·Status: COMPLETED
-
Preoperative (Chemo)Radiotherapy for Locally Recurrent Rectal Cancer
NCT06617052 ·Status: NOT_YET_RECRUITING
-
Oral Probiotics on Radiation Enteritis Stage Ⅱ Induced by Pelvic Concurrent Chemoradiotherapy
NCT05032027 ·Status: UNKNOWN ·Phase: NA
-
A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects
NCT07319364 ·Status: RECRUITING ·Phase: PHASE1
-
Gut Microbiota Reconstruction for NSCLC Immunotherapy
NCT05008861 ·Status: UNKNOWN ·Phase: PHASE1
-
The Clinical Study of Adjuvant Chemotherapy on Intestinal and Urethral Flora in Patients With Gastric and Colon Cancer
NCT04198051 ·Status: UNKNOWN ·Phase: NA
-
Study on Consistency Evaluation for Drug Sensitivity of Patient-Derived Organoid Model From Cholangiocarcinoma Patients
NCT05634694 ·Status: UNKNOWN
-
An Exploratory Study on Microbial Biomarkers Associated With the Efficacy of Neoadjuvant Therapy
NCT07263620 ·Status: RECRUITING
-
Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer
NCT05079503 ·Status: UNKNOWN ·Phase: NA
-
Validate the Dosimetric Parameters That Correlate With Acute Hematologic Toxicity (HT) in Patients With Rectal Cancer
NCT02630056 ·Status: UNKNOWN
-
Establishment of Individualized Immunotherapy Strategy and Platform Based on Changes of Intestinal Microbiota
NCT05065515 ·Status: UNKNOWN
-
Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients
NCT00502502 ·Status: COMPLETED
-
Prospective Assessment of Symptoms and Quality of Life in Rectal Cancer Patients Receiving Chemo-Radiotherapy
NCT00414232 ·Status: COMPLETED
-
Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer
NCT05414461 ·Status: COMPLETED ·Phase: PHASE2
-
Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies
NCT06041815 ·Status: UNKNOWN
-
Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer
NCT06346093 ·Status: RECRUITING ·Phase: NA
-
The Prognostic Impact Of The Neutrophil To Lymphocyte Ratio In Patients With Locally Advanced Rectal Cancer
NCT05673343 ·Status: UNKNOWN
-
To Explore the Diversity of Intestinal Flora in Patients With Advanced HCC Combin ed With Anti-PD-1 and Targeted Drug Therapy and the Correlation Between Metabolites and Therapeutic Effect
NCT04101747 ·Status: UNKNOWN
-
Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis
NCT02453490 ·Status: TERMINATED ·Phase: PHASE3
-
Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer
NCT02423226 ·Status: COMPLETED ·Phase: PHASE2
-
Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients
NCT02510118 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor
NCT01048463 ·Status: UNKNOWN ·Phase: PHASE3